sorafenib has been researched along with dabrafenib in 10 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (dabrafenib) | Trials (dabrafenib) | Recent Studies (post-2010) (dabrafenib) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 825 | 107 | 808 |
| Protein | Taxonomy | sorafenib (IC50) | dabrafenib (IC50) |
|---|---|---|---|
| Receptor-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | 0.077 | |
| GTPase KRas | Homo sapiens (human) | 5.88 | |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.15 | |
| Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | 0.026 | |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0033 | |
| TGF-beta receptor type-1 | Homo sapiens (human) | 3.7 | |
| Receptor-interacting serine/threonine-protein kinase 3 | Homo sapiens (human) | 0.126 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Agianian, B; Gavathiotis, E | 1 |
| Chen, F; Zhuang, C | 1 |
| Allegra, M; Bahadoran, P; Ballotti, R; Giacchero, D; Hofman, P; Lacour, JP; Le Duff, F; Long-Mira, E; Passeron, T | 1 |
| Fiskus, W; Mitsiades, N | 1 |
| Lou, L; Quan, H; Wang, H | 1 |
| Fulda, S | 1 |
| Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM | 1 |
| Anbar, HS; El-Gamal, MI; Jeon, HR; Kwon, D; Lee, BS; Oh, CH; Tarazi, H | 1 |
| Chen, WY; Chou, TC; Lee, YY; Lin, SF; Lu, YL; Wong, RJ; Wu, MH; Yeh, CN | 1 |
4 review(s) available for sorafenib and dabrafenib
| Article | Year |
|---|---|
Current Insights of BRAF Inhibitors in Cancer.
Topics: Animals; Drug Discovery; Humans; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf | 2018 |
Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives.
Topics: Animals; Cell Line, Tumor; Drug Development; Humans; Molecular Structure; Necroptosis; Protein Kinase Inhibitors; Receptor-Interacting Protein Serine-Threonine Kinases | 2020 |
Repurposing anticancer drugs for targeting necroptosis.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Apoptosis; Drug Repositioning; Humans; Imidazoles; Indazoles; Necrosis; Oximes; Pyridazines; Pyrimidines; Reperfusion Injury; Sorafenib; Sulfonamides; Systemic Inflammatory Response Syndrome; Vemurafenib | 2018 |
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib | 2019 |
6 other study(ies) available for sorafenib and dabrafenib
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
Topics: Aged; Antineoplastic Agents; Arginine; Back; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Indoles; Leucine; Lung Neoplasms; MAP Kinase Signaling System; Melanoma; Niacinamide; Oximes; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2013 |
B-Raf Inhibition in the Clinic: Present and Future.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Imidazoles; Indoles; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Oximes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib | 2016 |
AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Topics: Antineoplastic Agents; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imidazoles; Mutation; Niacinamide; Oximes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Sorafenib; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies.
Topics: Antineoplastic Agents; Carbamates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Molecular Dynamics Simulation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quantitative Structure-Activity Relationship; Sorafenib; Sulfonamides; Thiazoles; Vemurafenib | 2020 |
Therapeutic inhibition of ATR in differentiated thyroid cancer.
Topics: Adenocarcinoma; Animals; Ataxia Telangiectasia Mutated Proteins; Humans; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2023 |